GlassScriptPhysician profile
Samuel H Lee
NPI 1306173893
$200,359.57
in general payments reported to CMS, 2019-2025
28 companies · $40K in 2025
The $40K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,018 · 2021: $28K · 2022: $21K · 2023: $48K · 2024: $49K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $49K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Consulting Fee: $17K · Long Term Medical Supply Or Device Loan: $16K · Travel and Lodging: $13K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $49,390.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,265.00 |
| Consulting Fee | $17,292.50 |
| Long Term Medical Supply Or Device Loan | $16,402.72 |
| Travel and Lodging | $13,087.23 |
| Food and Beverage | $10,466.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $73,569.84 | 2019-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Dompe US, INC. | $70,625.56 | 2019-2025 | Oxervate |
| Glaukos Corporation | $31,222.76 | 2020-2025 | Epioxa, Ce-Marked Kxla System, Travoprost Intraocular Implant - Idose |
| Biotissue Holdings INC. | $18,728.49 | 2019-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $1,609.12 | 2019-2024 | Tecnis Iol, Veritas Vision System, Catalys System |
| Allergan, INC. | $1,159.68 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $624.18 | 2019-2023 | |
| Rxsight INC | $362.31 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Abbvie INC. | $296.24 | 2022-2025 | |
| Shire North American Group INC | $256.27 | 2019 | |
| Apellis Pharmaceuticals, INC. | $234.11 | 2024-2025 | Syfovre |
| Oyster Point Pharma, INC. | $232.48 | 2022-2025 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $191.81 | 2022-2025 | Acthar |
| Bausch & Lomb Americas INC. | $183.11 | 2024-2025 | Miebo, Scoutpro Osmolarity System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $163.54 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $154.53 | 2019-2023 | Cequa |
| Kala Pharmaceuticals, INC. | $147.14 | 2021 | |
| Astellas Pharma US INC | $122.83 | 2023 | |
| Aerie Pharmaceuticals, INC. | $114.84 | 2021 | |
| Stimlabs LLC | $85.26 | 2025 | Geistlich Derma-Gide, Corplex P |
| Rayner Intraocular Lenses Limited | $70.99 | 2023-2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Horizon Therapeutics Plc | $55.87 | 2022-2023 | Tepezza |
| Sight Sciences, INC. | $41.97 | 2022-2024 | Omni Surgical System |
| Harrow Eye, LLC | $40.82 | 2024 | Vevye, Iheezo |
| Tarsus Pharmaceuticals, INC. | $30.97 | 2024 | Xdemvy |
| Amgen INC. | $19.85 | 2024 | Tepezza |
| Thea Pharma INC. | $15.00 | 2024 | Iyuzeh |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.